You just read:

Real-World Evidence Shows Oral INVOKANA® 300 mg Demonstrates Comparable A1C Reduction and Control to Injectable GLP-1 Receptor Agonists

News provided by

Janssen Pharmaceuticals, Inc.

May 05, 2017, 18:00 ET